*This study is currently seeking funding *

A FIRST OF ITS KIND STUDY DRIVING INNOVATION

 

The Castleman Disease Collaborative Network SPEED II study is the most comprehensive ‘omics’ study ever conducted in Castleman disease (CD). With samples from over 100 individuals with CD, related disorders, and healthy controls, the study offers unprecedented promise to accelerate understanding of disease mechanisms and provide insights for development of personalized therapies.

The SPEED II Study will identify target biomarkers for treatments for the approximately 60% of patients that do not respond to the only FDA-approved iMCD therapy. Also, control samples from healthy individuals and patients with related diseases will help to identify diagnostic biomarkers

 

SPEED II WILL PRODUCE A GOLDMINE OF HIGH-IMPACT CLINICAL DATA

 

This Study will evaluate 1,129 proteins in the blood of 79 patients (2 samples from each patient) and ~40 controls. It will cost $1,129 per sample. ~$250,000 is needed to fund the study.

 You can donate to this study by clicking here.